A limitation of CBTp is the lack of availability. It is estimated that only 1 in 10 people that could benefit from the therapy get access to it, despite it being recommended by NICE as the treatment for patients with SZ. This figure is even lower in some areas. This means that although CBTp is effective, it is not available to all SZ patients.